 Type III RPGN may be isolated to the glomerulus (primary, or idiopathic) or associated with a systemic disease (secondary).In most cases of the latter, the systemic disease is an ANCA-associated vasculitis such as granulomatosis with polyangiitis, microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis.Therapy consists of a combination of rituximab, corticosteroids, and cyclophosphamide, with a substitution of azathioprine for cyclophosphamide after a ninety-day initial period being another option When remission is achieved, immunosuppressants are still used, usually corticosteroids with azathioprine or rituximab infusions.